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Abstract
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Background—Erythropoiesis stimulating agents (ESAs) are neuroprotective in cell and animal
models of preterm birth. Prematurity has been shown to alter neurometabolite levels in children in
studies using proton magnetic resonance spectroscopy (1H-MRS). We hypothesized that ESA
treatment in premature infants would tend to normalize neurometabolites by 4-6 years of age.
Design/Methods—Children in a longitudinal study of neurodevelopment underwent MRI and
1H-MRS at approximately 4 and 6 years of age. Prematurely born children (500-1250 grams birth
weight) received ESAs (erythropoietin or darbepoetin) or placebo during their neonatal
hospitalization, and these groups were compared to healthy term controls. 1H-MRS spectra were
obtained from the anterior cingulate (gray matter) and frontal lobe white matter, assessing
combined N-acetylaspartate and N-acetylaspartylglutamate (tNAA), myo-inositol, choline
compounds (Cho), combined creatine and phosphocreatine, and combined glutamate and
glutamine.
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Results—No significant (p≤0.5) group differences were observed for any metabolite level.
Significant age-related increases in white matter tNAA and Cho were observed, as well as a trend
for increased gray matter tNAA.
Conclusions—Neither prematurity nor neonatal ESA treatment were associated with differences
in brain metabolite levels in the children of this study at a significance level of 0.05. These
findings suggest that earlier differences that may have existed had normalized by 4-6 years of age
or were too small to be statistically significant in the current sample.
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Introduction
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Neurodevelopmental disabilities such as cerebral palsy, cognitive delays, and learning and
attention deficits during school age figure prominently in the outcomes of very low birth
weight (VLBW) infants [1]. However, successful neuroprotective interventions have yet to
be developed[2] (Back, 2015). Recent studies in animals and humans have shown that
erythropoiesis stimulating agents (ESAs) such as erythropoietin (Epo) and darbepoetin
(Darbe) have trophic, anti-inflammatory, and anti-apoptotic effects on neurons and
oligodendrocytes, suggesting a strong neuroprotective potential of ESAs in the treatment of
VLBW infants[3]. Whether ESAs can normalize brain structural or metabolic deficits in
VLBW infants, though, remains to be evaluated.
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Proton magnetic resonance spectroscopy (1H-MRS) has revealed altered levels of
neurochemicals soon after premature birth[4-18] which, in some studies, have been shown to
be associated with structural brain abnormalities evident on magnetic resonance imaging
(MRI)[5,10,11,18,17]. The variety of 1H-MRS methods applied in these studies (e.g.,
different pulse sequences, echo times, analysis methods, with or without correction for tissue
composition) and regions examined (e.g., cortical gray matter, white matter, cerebellum,
thalamus, hippocampus), combined with diverse statistical methods, have made comparing
their results challenging. However, generally, the metabolite signals measured are from the
neuronal metabolite N-acetylaspartate (NAA), often assessed in combination with its
overlapping spectral neighbor N-acetylaspartatylglutamate (NAAG); choline groups,
primarily on the membrane lipid metabolites phosphocholine and glycerophosphocholine
(Cho); myo-inositol (mI), an osmolyte found primarily in glia; lactate; taurine; and
glutamate (Glu) and/or combined Glu and overlapping glutamine (the combination
designated as Glx). Most studies assessed differences in the levels of the metabolites either
in terms of their ratios with Cr or Cho, with the assumption that the latter do not vary
between groups or with time, or as concentrations, estimated using the tissue water signal as
a reference.
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Few studies have examined metabolic abnormalities in preterm-born children beyond the
neonatal period. Bathen et al[19] found no significant metabolic differences in left frontal
white matter between preterm-born children, term-born children with low birth weight, and
healthy term control subjects who underwent 1H-MRS at about 15 years of age. However,
group membership in this study could be identified with high accuracy by neural network
and discriminant analysis methods. Gimenez et al[20] found that NAA+NAAG and Cr in the
hippocampus of preterm-born adolescents at about 15 years of age were lower than these
metabolites in the hippocampus of age-matched term-born adolescents, and that gestational
age at birth across both groups correlated with NAA+NAAG, Cr, mI, and hippocampal
volume. In a previous study on anterior cingulate and frontal periventricular white matter in
preterm-born children and term control subjects evaluated at 18-22 months or 3-4 years [21],
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we found significant differences in metabolites only in frontal white matter. At 18-22
months NAA+NAAG was lower in preterm-born children, and at 3-4 years preterm Cr and
NAA/Cho were lower and Glx/Cr and Cho/Cr were higher in preterm-born children.

Author Manuscript

To date, no studies have sought to determine whether ESAs improve the neurometabolic
outcome of preterm birth, either during the perinatal period or later in development. In the
current study, we address the question of long-term metabolic improvement in a cohort of
term- and preterm-born children examined at approximately 4 years of age and in a subset of
these children returning at approximately 6 years of age, ages at which rapid developmental
changes in neurometabolite levels are expected to have largely stabilized[22,13]. We
examined 1H-MRS data from single voxels placed in frontal white matter and in the anterior
cingulate gyrus, a region that is involved in attention and self-regulation, among other
cognitive functions, and is thus a critical structure in neurodevelopment[23]. The pretermborn subjects had previously been randomized to receive Epo, Darbe or placebo within 48
hours of birth as part of a larger study examining cognitive and other neuroimaging
measures of neurodevelopment.
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In a larger sample of this study, subjects who had received Epo or Darbe had significantly
higher composite cognitive scores and decreased neurodevelopmental impairment relative to
subjects who had received placebo[24,25]. Neuroimaging data from a subset of this sample
revealed significantly higher mean fractional anisotropy (FA), a measure of white matter
health, in ESA-treated preterm-born female children at 4 years of age relative to untreated
preterm-born females, but no other significant group differences in either FA or cortical
thickness between groups [26]. Additionally, in the combined sample, significant
correlations were found between FA and Full-Scale IQ and Verbal IQ, although there was no
significant relationship between Full-Scale IQ and FA among just the preterm children.
In the subset of subjects with adequate 1H-MRS data reported here, we similarly searched
for group metabolic differences that would reflect the cognitive differences observed. Hence,
we hypothesized that neurometabolites would be altered in placebo-treated children and,
furthermore, demonstrate a trend toward normalization in ESA-treated children.

Methods
Eligibility

Author Manuscript

The subjects were children previously enrolled in a randomized trial of Darbe, Epo,
(collectively referred to as the ESA group) or placebo (the placebo group) (NCT#
00334737) performed at the University of New Mexico, the University of Colorado, the
University of Utah, and Intermountain Health Care. Briefly, infants were eligible for the
initial randomized masked trial if they weighed 500-1,250 grams at birth, were ≤48 hours of
age, and were expected to survive the first days of life (as determined by the attending
neonatologist). Infants with trisomy 21, 18 or 13, significant congenital anomalies (including
known neurologic anomalies), hypertension, seizures, thromboses, hemolytic disease, or
already receiving Epo were ineligible for study.
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Former preterm children in the RCT surviving to follow up were then enrolled in the BRITE
(Brain Imaging and Developmental Follow up of Infants Treated with ESAs) Study in order
to continue following development and perform imaging. In addition, children born at term
(37-41 weeks gestation) without complications (no prolonged hospitalization,
hyperbilirubinemia, sepsis, hypoglycemia or prenatal drug exposure) were enrolled to serve
as a healthy control group. All subjects underwent magnetic resonance imaging and 1HMRS at approximately 4 and 6 years of age. Only the 1H-MRS data acquired at the New
Mexico site are presented in this report. The study was approved by the Institutional Review
Board at the University of New Mexico. Parental consent was obtained from all participating
families in the BRITE Study.
Magnetic Resonance Imaging and Spectroscopy
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Scanning was performed at night during natural sleep (all full term children) or with light
chloral hydrate sedation (50 mg/kg orally), used for VLBW children who did not fall asleep
naturally. Parents remained with the children during the scanning. Once children were
asleep, scanning took 45 to 60 minutes to complete. Ear plugs and head phones were placed
on children’s ears for noise protection. All magnetic resonance imaging scans were
performed on a Siemens 3 T Trio Tim scanner using the standard 12-channel phased array
head coils provided with the system. Sagittal T1-weighted anatomical images were obtained
with a multi-echo three dimensional Magnetization Prepared Rapid Acquisition Gradient
Echo sequence. Single voxel 1H-MRS data were obtained from a frontal gray matter voxel
along the anterior cingulate gyrus (AC) and from a frontal white matter (WM) voxel with a
point-resolved spectroscopy sequence (PRESS) sequence, with and without water
suppression (TR/TE=1500/40ms, 192 averages with water suppression, 16 averages without
water suppression). The transmitter frequency was set to 2.3 ppm for the acquisition of the
metabolite spectrum and to 4.7 ppm (water resonance) for the acquisition of the water
spectrum to reduce the chemical shift artifact. The AC and WM voxels were both 2.5 cm ×
1.5 cm × 1 cm (3.75 cm3) in size. The AC voxel was located along the interhemispheric
fissure in the anterior cingulate gyrus with the long axis along the fissure and the 1.5-cm
dimension parallel to the fissure. The white-matter voxel was located in in a WM region to
the left of the AC. Both locations and example spectra from one subject are shown in Figure
1.

Author Manuscript
1H-MRS

data processing
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The 1H-MRSI data were analyzed with LCModel[27] using tissue water as a concentration
reference. The 1H-MRS signals analyzed were from combined N-acetylaspartate and Nacetylaspartyl glutamate (tNAA), choline containing compounds (Cho), combined creatine
and phosphocreatine (Cr), myo-inositol (mI), and combined glutamate and glutamine (Glx).
We used the LCModel standard deviation of the fit to the peak of interest, related to the
Cramer-Rao lower bounds, as a criterion to exclude data of poor quality from the final
analysis. If this statistic was greater than 20% for the peak of interest, the data were
excluded. Additionally, if the signal-to-noise ratio of the spectrum, evaluated by LCModel as
the ratio of the NAA peak height to the root mean square of the residuals to the fit, was less
than 10, the data were excluded. The results from LCModel were corrected for cerebrospinal
fluid (CSF), WM, and gray matter (GM) content (partial volume effects) as previously
Pediatr Radiol. Author manuscript; available in PMC 2019 March 01.
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reported[28]. The normalized gray matter fraction (fGM/(fGM + fWM) of the AC voxel was
generally high (0.94 ± 0.04), while the GM contribution to the WM voxel varied
considerably more (0.27 ± 0.14). For this reason, an additional inclusion criterion in the
analysis of the WM metabolite data was that the WM composition be greater than 0.5.
Statistical Analysis

Author Manuscript

In order to account for multiple metabolite comparisons as well as variance due to voxel
tissue composition, group comparisons of metabolite levels in each 1H-MRS voxel (AC or
WM) at each age (4 and 6 year visits) were made with multivariate analysis of covariance
(MANCOVA) followed by univariate analyses on each metabolite using IBM SPSS (version
24.0). Both one-way (treatment group) and two-way (treatment group and sex, with and
without a treatment group-by-sex interaction term) MANCOVAs were performed. A small
number of outliers in each treatment group data set were identified (3 × interquartile range)
and analyses were performed with and without them to test their impact on the results.
Longitudinal effects were examined with repeated measures MANOVA. Our statistical
power varied slightly across analyses, due mostly to variable numbers of participants with
high-quality data. A post hoc power analysis using the G*Power calculator [29] based on the
4 year-old AC sample, the largest in the study, estimated that a medium to large effect size
(Cohen’s f 2 ≥ .28) would be needed to observe a significant group effect in that sample with
a statistical power of 0.8.

Author Manuscript

The concentrations of NAA, Cr, mI, and Glu are substantially higher in GM than in WM.
Hence, variability in the GM-WM composition of the voxel can be expected to contribute
significantly to the total variance in the data and potentially bias group differences. To
account for this variance in the analyses of both AC and WM data, the normalized gray
matter fraction was entered as a covariate in all MANCOVA models.

Results

Author Manuscript

Demographic and other background data on participants is provided in Table 1. During the
initial 4 year visit, anterior cingulate 1H-MRS datasets of adequate quality were obtained
from 52 subjects: 22 term controls (10 male [M]/12 female [F]), 15 preterm placebo (9 M/6
F), and 15 preterm ESA treated (7 M/8 F). Adequate white matter data sets were obtained
from 44 subjects: 15 term controls (8 M/7 F), 16 placebo (6 M/10 F), 13 ESA treated (7 M/6
F). During the 6 year follow-up visit, adequate anterior cingulate 1H-MRS datasets were
obtained from 41 returning subjects: 12 term controls (6 M/6 F), 12 placebo (6 M/6 F), and
17 ESA treated (10 M/7 F). Adequate white matter data sets were obtained from 30 of these
subjects: 8 term (4 M/4F), 10 placebo (5 M/5 F), and 12 ESA treated (4 M/8 F). Because of
missing data at each test session, the number of participants with complete, high quality data
at both time points was reduced: 35 participants (10 placebo, 13 ESA treated, and 12 term
controls) had longitudinal AC data and 26 (10 placebo, 9 ESA treated, 7 term controls had
longitudinal WM data.
In order to maximize use of all data, we first conducted analyses of the visit 1 data (4 years),
using one MANCOVA for the AC data and one for the frontal WM data. Preliminary
analyses showed no relationships between age and any metabolite levels within either age
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group; hence, this variable was not included in the analyses described below. In each
MANCOVA, sex and group (placebo, treated, term) were fixed factors, while the relevant
gray matter fraction was entered as a covariate. For visit 1 AC data, no significant
multivariate effects of group were observed (F(10, 84) = .862, p = .57, partial eta squared = .
09). Similarly, for visit 2 AC data (6 years), no significant multivariate effects of group were
observed (F(10, 64) = .823, p = .608, partial eta squared = .114). For visit 1 WM data, we
again noted no significant multivariate effects of group, (F(10, 74) = .570, p = .833, partial
eta squared = .072). And for visit 2 WM data, no significant multivariate effects of group
were noted (F(10, 48) = .820, p = .611, partial eta squared = .146).
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For participants with high quality data sets on both occasions, we conducted two
multivariate repeated measures analyses, one for AC and one for WM data. Age represented
the repeated measures factor, sex and group were fixed factors, and voxel gray matter
fractions on both occasions were included as covariates. For the AC, there was no significant
multivariate effect of group, F(10, 46) = 1.244, p = .290, partial eta squared = .213. Nor was
any significant interaction observed between group and any other factor in the model. For
the frontal WM analysis, there was again no significant multivariate effect of group, F(10,
30) = .664, p = .748, partial eta squared = .181. Further, no significant interaction was
observed between group and any other factor in the model.
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Finally, we investigated possible age-related changes in metabolites across the entire sample
using paired t-tests. Of the 10 metabolites examined, five each from GM and WM, two were
found to significantly differ with age. WM tNAA increased from 12.721 (SD = .932) to
13.485 (SD = 1.058), t(25) = 3.449, p = .002). Also, WM Cho increased from 3.192 (SD + .
408) to 3.396 (SD = .490), t(25) = 2.277, p = .032. A trend was noted for increased AC
tNAA, from 14.187 (SD = .889) to 14.574 (SD = .830), t(33) = 1.870, p = .07.

Discussion

Author Manuscript

During the perinatal period the fetal brain is increasing in size, shape and complexity: and
normal brain development is especially vulnerable to interruption by hypoxia-ischemia and
associated oxidative stress, inflammation, and excitotoxicity[3,30]. Although the transition
from fetal to early postnatal life is the period of greatest vulnerability, the infant remains at
risk for brain injury throughout the period of oligodendrocyte development, approximately
33 weeks post-menstrual age. Treatment with neuroprotective agents during this period have
the greatest chance for improving long term neurodevelopmental outcomes in preterm
infants at highest risk for neurodevelopmental impairment. ESAs such as Epo have been
shown to ameliorate neural injury in animal models of neonatal ischemia[31-34] and
improve neurodevelopmental outcome in premature human neonates administered these
agents[3,24,25]. The neurocognitive outcomes we reported at 2 years in this cohort [25]
remained significantly better at 4 and 6 years of age in children who as preterm infants
received ESAs during their initial hospital stay (Table 3) [25,35]. At 4 years of age, full scale
IQ was 91.1 ±17.5 in ESA recipients compared with 79.2 ±18.5 in placebo recipients (p =
0.036), and performance IQ was 93.0±17.0 in ESA recipients compared with 79.5±19.5 in
placebo recipients (p=0.018).
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A number of studies have established evidence of metabolic abnormalities in the brains of
preterm infants within weeks of birth. In an early 1H-MRS study, NAA/Cr was found to be
lower in the cerebellum of preterm neonates relative to its level in term neonates[4].
Examining only preterm neonates, Robertson et al[5] found that lactate/Cr and mI/Cr were
higher in posterior periventricular white matter in infants with white matter abnormalities on
MRI. In a cross sectional study comparing term to preterm neonates within a few weeks of
birth, Kreis et al[6] examined correlations between gestational age and several metabolite
concentrations, including NAA, Cho, Cr, mI, lactate, and glutamate. No significant
differences were found between groups with respect to any metabolite in the cortical gray,
thalamic, or white matter regions examined. Similarly, Roelants-van Rijn et al[7] measured
NAA/Cho, mI/Cho, lactate/Cho and Glx/Cho in basal ganglia and periventricular white
matter in preterm and term neonates and found associations with gestational age and
NAA/Cho (positive) and mI/Cho (negative), but no significant differences between the
preterm and term groups.

Author Manuscript
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In a more recent study, Bluml et al[13] showed that the trajectories of NAA and Cho levels
in a large group of term and preterm neonates differed significantly in parietal white matter
over a cross-sectional sample with gestational ages from 270 to 380 days. No significant
differences in any metabolite examined (NAA, Cr, Cho, glutamate, taurine and mI) were
found in gray matter, and the white matter differences approached zero at the end of the
gestational age range, suggesting that metabolite levels in preterm born infants normalize
relatively soon after birth. Koob et al[17] found lower levels of Cr, taurine, and Glx in the
centrum semiovale of preterm neonates relative to those in term neonates examined at 40
weeks of gestational age. along with evidence of white matter pathology with diffusion
tensor imaging (DTI). Infants with white matter pathology evident on clinical MRI images
(e.g., atrophy, hemorrhage, ventriculomegaly) were excluded in this study. However, studies
by Wisnowski el al. have shown that punctate white matter lesions evident on MRI in
preterm neonates were associated with greater glutamine and lower NAA in white matter,
while more diffuse white matter abnormalities were associated with lactate and lower
mI[11,16]. A subsequent analysis of data from this sample revealed that lower NAA and
higher lactate and Cho in white matter were associated with both lower white matter lesion
load and thalamic volume[18]. Similarly, Card et al[10], in a study on preterm infants
shortly after birth and then at a term-equivalent number of weeks, observed that white matter
abnormalities were associated with lower NAA/Cr in the basal ganglia, and that Clinical
Risk for Babies II and Apgar scores were associated with higher lactate/Cr or lactate/Cho in
this region. In a large voxel in frontal gray and white matter, Kwon et al[15] found lower
glutamate and gamma-aminobutyric acid (GABA) in preterm neonates relative to these
metabolites in term neonates, and that GABA was more strongly correlated with a fMRI
measure of resting state connectivity in preterm neonates.
Studies have also examined the relationship between metabolite levels soon after preterm
birth and cognitive performance at some later age. Augustine et al[8] measured NAA/Cho
within a few weeks of birth in both the thalamus and basal ganglia and found no significant
correlations between this ratio and Bayley cognitive scores at 18 to 24 months of age.
However, Van Kooij et al[9] measured cerebellum volume and metabolite levels after birth in
preterm neonates and found that both volume and NAA/Cho correlated with Bayley scores
Pediatr Radiol. Author manuscript; available in PMC 2019 March 01.
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at 24 months of age, though the lack of a term-born control group in this study prohibits
inferences as to whether these correlations are related to prematurity. Similarly, Kendall et
al[14] reported that higher Cho/Cr and lower NAA/Cho in the periventricular white matter of
a cohort of preterm infants measured shortly after birth predicted impaired motor outcome at
the age of 1 year, with no comparison to term infants. Bapat et al[12] found lower NAA/Cho
in subventricular white matter and frontal cortex of preterm infants relative to these ratios in
term infants, and that NAA/Cho in subventricular white matter and frontal cortex and
NAA/mI in subventricular white matter correlated with Bayley mental scores at 18-22
months corrected for age in both groups.
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Based on the most consistent outcomes from the studies on neonates, though widely ranging
in methodology, one might conclude that 1) the primary regions of metabolic abnormalities
during the perinatal period of premature birth are in white matter and 2) these abnormalities
are associated with evidence of white matter structural abnormalities evident on MRI.
Only a few 1H-MRS studies have shown evidence of long term metabolic deficits in
preterm-born children[19,21,20]. In spite of the very important implications of these
findings, in terms of the possible mechanisms that might underlie lifelong deficits in
learning and cognition in preterm-born children, there have been no reports on the
replication of these studies in larger, independent cohorts.
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To our knowledge, the present study is the first to report the long-term neurometabolic
effects of ESA treatment in preterm-born children. Though significant age-related effects
and a pattern of lower mean tNAA, Cho, and mI in the placebo-treated group relative to the
ESA group and term group were observed at both 4 and 6 years, no metabolite difference
among treatment groups was significant in multivariate, univariate or repeated measures
analyses of the data at the 0.05 level of significance. Given our sample sizes and statistical
model, we had adequate power to observe only medium to large statistically significant
effect sizes across the central comparison of placebo and ESA treated children. Thus, we can
not rule out small effects of prematurity or treatment on neurometabolites, which may still
be clinically meaningful. Aggregating results of similar studies through meta-analysis may
help detect smaller effect sizes.
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The current study differed from our previous study of preterm- and term-born children[21],
in which significant metabolite differences in WM were observed, not only in terms of the
subject ages (18-22 months and 3-4 years vs. 4 years and 6 years) but in the statistical
analysis applied. Due to a high number of outliers in the former study, we used a nonparametric method for group comparisons (Mann-Whitney-Wilcoxon) which precluded
adjusting the metabolite levels for tissue GM-WM composition, a source of variance that
proved to be consistently significant in the various analyses on the current data. The
variability in GM composition was particularly high at the periventricular WM voxel
location. Our present findings underscore the need to account for GM-WM composition
when analyzing 1H-MRS data from brain tissue. Metabolite levels can vary substantially
between GM and WM and if there are group differences in tissue composition at a voxel
location, failing to control for this variance could introduce a systematic bias in the results.
Furthermore, it is worth noting that only a limited number of brain metabolites can be
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measured relatively reliably by in vivo 1H-MRS, with a variability that is typically of the
order of 5-10% in cooperative adult subjects[26]. Given these caveats, along with the
inconsistent results of the small number of studies on the long-term neurometabolic effects
of prematurity, further studies are needed to probe the underlying causes of the persistent
cognitive deficits of prematurity. Additionally, in view of the more consistently significant
findings of 1H-MRS studies performed soon after preterm birth, it may be worthwhile to
examine the effects of ESA treatment on brain metabolism during this early period of life.
Such studies, for example, could explore the possibility that ESA treatment causes early
neurometabolic differences that resolve over time but are part of processes leading to
enduring benefits in brain function such as improved cortical connectivity.
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In conclusion, no significant differences in metabolite levels were observed at either 4 or 6
years of age between preterm-born children treated shortly after birth with ESAs, pretermborn children who received a placebo after birth, and term-born children. With the caveat
that the study was not adequately powered to observe statistically significant small effect
sizes, these results suggest that earlier neurometabolite differences between preterm and full
term infants that may have existed, such as those observed in other studies, have resolved by
4 years of age and, therefore, the beneficial effect of ESA treatment on neural development
in this age range is achieved through mechanisms not involving the normalization of
persistent deficits in these metabolites. Future carefully conducted and adequately powered
studies are needed to characterize the effect of ESA treatment on neonatal neurometabolism
and the mechanisms underlying long term benefits of ESAs on neurodevelopment.
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All procedures performed in studies involving human participants were in accordance with
the ethical standards of the institutional and/or national research committee and with the
1964 Helsinki declaration and its later amendments or comparable ethical standards.
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Example of voxel placement (overlaid rectangles) for the anterior cingulate (A) and frontal
white matter (B) in one male 4 year-old subject and spectra from these locations (C=anterior
cingulate, D=white matter) with LCModel fit overlays. NAA = N-acetylaspartate ; NAAG =
N-acetylaspartatylglutamate; Cho = total choline groups; mI = myo-inositol; Glx =
glutamate + glutamine.
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confidence intervals of these differences (CI(±)). tNAA = N-acetylaspartate + N-acetylaspartatylglutamate; Cho = total choline groups; mI = myoinositol; Glx = glutamate + glutamine.
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Summary of neurocognitive outcomes at 4 and 6 years of age.
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